Melanoma Monday: Vitamin D levels affect response, machine learning predicts recurrence
Click Here to Manage Email Alerts
Today is Melanoma Monday.
The American Academy of Dermatology established the observance — which falls on the first Monday of May — to raise awareness about causes and symptoms of melanoma, the deadliest form of skin cancer.
The effort also emphasizes the importance of sun protection and other strategies to reduce melanoma risk.
In conjunction with Melanoma Monday, Healio presents the following updates in melanoma research and treatment:
1. Maintenance of normal vitamin D levels during anti-PD-1 immunotherapy should be standard procedure for patients with advanced melanoma to allow for better treatment outcomes. Read more.
2. The addition of an mRNA-based cancer vaccine to pembrolizumab (Keytruda, Merck) extended RFS among patients with resected high-risk melanoma. Read more.
3. L-fucose, a nontoxic plant sugar found in red and brown seaweed, may increase the number and strength of tumor-infiltrating lymphocytes and improve upon the effectiveness of immunotherapy. Read more.
4. The addition of all-trans retinoic acid to pembrolizumab conferred benefit to patients with metastatic melanoma. Read more.
5. Researchers developed machine learning-based methods to predict which patients with early-stage melanoma have the highest risk for disease recurrence. The methods could help reveal those who may benefit from greater surveillance or adjuvant immunotherapy. Read more.
6. Fecal microbiota transplant from healthy donors may lower primary resistance to immunotherapy with anti-PD-1 agents among patients with advanced or metastatic melanoma. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts